4//SEC Filing
Balthaser Kevin 4
Accession 0001415889-25-006494
CIK 0001557746other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:15 PM ET
Size
12.8 KB
Accession
0001415889-25-006494
Insider Transaction Report
Form 4
Balthaser Kevin
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-01+1,100→ 90,960 total - Exercise/Conversion
Restricted Stock Units
2025-03-01−2,375→ 2,375 total→ Common Stock (2,375 underlying) - Exercise/Conversion
Restricted Stock Units
2025-03-01−1,100→ 0 total→ Common Stock (1,100 underlying) - Exercise/Conversion
Common Stock
2025-03-01+2,375→ 93,335 total - Tax Payment
Common Stock
2025-03-01$1.99/sh−727$1,447→ 92,608 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
- [F4]The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001957554
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:15 PM ET
- Size
- 12.8 KB